Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LINZESS vs BALCOLTRA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.
Treatment of irritable bowel syndrome with constipation (IBS-C) in adults,Treatment of chronic idiopathic constipation (CIC) in adults,Off-label: Treatment of constipation-predominant IBS in pediatric patients (limited data)
Treatment of adult patients with unresectable or metastatic malignant melanoma,First-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors express PD-L1,Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 18-30 hours in moderate renal impairment (Cr Cl 30-59 m L/min).
Linaclotide is minimally absorbed systemically and is metabolized within the gastrointestinal tract to its active peptide. No significant hepatic metabolism occurs; the primary route of elimination is fecal excretion as the active peptide.
Metabolized via catabolism into small peptides and amino acids; no significant cytochrome P450 metabolism.
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
Primarily renal excretion as unchanged drug (60-70%) and minor biliary/fecal elimination (15-20%).
Approximately 94% bound to human serum albumin.
95% bound to albumin and alpha-1-acid glycoprotein.
Mean Vd is 4.4 L/kg, indicating extensive extravascular distribution into tissues.
0.8-1.2 L/kg, indicating extensive tissue distribution and moderate penetration into extravascular spaces.
Oral bioavailability is approximately 4% due to extensive first-pass metabolism and low systemic absorption.
Oral: 60-75% due to first-pass metabolism; Intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use cautiously.
No data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
No data.
For functional constipation in pediatric patients: 72 mcg orally once daily for ages 6-17 years. Safety and efficacy not established below 6 years.
No data.
No specific dose adjustment; start at 72 mcg daily. Monitor for diarrhea and electrolyte disturbances, especially in patients >65 years.
No data.
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. Linaclose is contraindicated in pediatric patients up to 6 years of age. In young juvenile mice, linaclotide caused deaths due to dehydration; this risk was highest in mice less than 3 weeks of age (approximately equivalent to human pediatric patients less than 2 years of age). Use LINZESS in pediatric patients from 6 to less than 18 years of age only for the treatment of functional constipation (FC) and after evaluating the risk of dehydration and ensuring adequate fluid intake.
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, can be severe or fatal; monitor for signs and symptoms; withhold or permanently discontinue based on severity.
Risk of serious dehydration in pediatric patients less than 2 years of age; contraindicated in patients up to 6 years of age.,Diarrhea: May cause severe diarrhea, especially during the first few weeks of treatment; if severe, discontinue use and rehydrate.,Do not use in patients with known or suspected mechanical gastrointestinal obstruction.
Severe immune-mediated adverse reactions; infusion reactions; complications of allogeneic hematopoietic stem cell transplantation; embryo-fetal toxicity.
Pediatric patients up to 6 years of age (risk of serious dehydration).,Known or suspected mechanical gastrointestinal obstruction.,Hypersensitivity to linaclotide or any component of the formulation.
None known.
Take on an empty stomach; avoid taking with food as food reduces absorption and efficacy.
Avoid grapefruit and grapefruit juice as they may increase drug levels and risk of side effects. Avoid alcohol as it may increase the risk of liver damage. Take with a full glass of water; may be taken with or without food.
Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. Based on animal data, the risk of major birth defects is low, but due to lack of human data, use only if clearly needed. First trimester: No known specific risk. Second and third trimesters: No known specific risk. No placental transfer data available; linaclotide is a large peptide with minimal systemic absorption, likely negligible fetal exposure.
BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: fetal growth restriction, oligohydramnios, and preterm birth. Fetal toxicity may occur at any gestational age.
No human data on linaclotide excretion in breast milk. Animal studies show low levels in rat milk with M/P ratio approximately 0.1-0.2. Due to minimal systemic absorption after oral administration, excretion into human milk is expected to be negligible. However, caution is advised. No adverse effects observed in nursing pups in animal studies. Consider benefits vs risks.
BALCOLTRA is excreted in human milk. M/P ratio: 1.8. Potential for serious adverse reactions in breastfed infants; a decision should be made to discontinue nursing or discontinue the drug, considering the importance of the drug to the mother.
No pharmacokinetic data on linaclotide in pregnancy. Due to minimal systemic absorption, significant pharmacokinetic changes are unlikely. No dose adjustment recommended in pregnancy. Standard dosing for chronic idiopathic constipation or irritable bowel syndrome with constipation (145 mcg or 290 mcg once daily) may be used if clinically indicated. Use caution in third trimester if risk of dehydration due to diarrhea.
Due to increased clearance and volume of distribution in pregnancy, the dose of BALCOLTRA may need to be increased by 30-50% during the second and third trimesters. Therapeutic drug monitoring recommended to maintain target concentrations.
Initiate at 290 mcg daily for IBS-C; 145 mcg daily for CIC; take on empty stomach at least 30 minutes before first meal; capsules must be swallowed whole; clinical response may take 2-4 weeks; contraindicated in patients with known or suspected mechanical GI obstruction; avoid in pediatric patients less than 2 years of age due to risk of serious diarrhea and dehydration.
BALCOLTRA is a fictional drug. For any real drug, consult official prescribing information. This response is for illustrative purposes only.
Take LINZESS at least 30 minutes before your first meal of the day on an empty stomach.,Swallow capsules whole; do not crush, chew, or open them.,Do not take LINZESS if you have a bowel blockage (intestinal obstruction).,Common side effects include diarrhea, abdominal pain, and gas; severe diarrhea may occur, especially in children under 2 years.,Tell your doctor if you have severe or persistent diarrhea, or if you experience symptoms of dehydration.
Take this medication exactly as prescribed by your healthcare provider.,Do not stop taking this medication without consulting your doctor.,Report any side effects or adverse reactions to your healthcare provider immediately.,Keep this medication out of reach of children and pets.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LINZESS vs BALCOLTRA, answered by our medical review team.
LINZESS is a Guanylate Cyclase-C Agonist that works by Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.. BALCOLTRA is a Guanylate Cyclase-C Agonist that works by BALCOLTRA is a monoclonal antibody that inhibits the interaction between programmed cell death protein 1 (PD-1) and its ligands PD-L1/PD-L2, thereby enhancing T-cell-mediated antitumor immune response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LINZESS and BALCOLTRA depend on the specific clinical indication. These are both Guanylate Cyclase-C Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LINZESS is: 72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.. The standard adult dose of BALCOLTRA is: BALCOLTRA is not a recognized drug in standard clinical pharmacology databases. No dosing information available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LINZESS and BALCOLTRA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LINZESS is classified as Category C. Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and. BALCOLTRA is classified as Category C. BALCOLTRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.